Evidence-Based Strategies for Achieving and Sustaining Full Remission in Depression: Focus on Metaanalyses

Canadian Journal of Psychiatry

Volumn 49, Issue 3 SUPPL. 1, 2004, Pages

  Lam, Raymond W ^a   Kennedy, Sidney H ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressants; Complementary therapy; Depressive disorders; Evidence based medicine; Light therapy; Metaanalysis; Psychotherapy

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DESIPRAMINE; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; ICOSAPENTAENOIC ACID ETHYL ESTER; IMIPRAMINE; LITHIUM; MIANSERIN; MIRTAZAPINE; OMEGA 3 FATTY ACID; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALTERNATIVE MEDICINE; BEHAVIOR THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXERCISE; FOLLOW UP; HUMAN; MAJOR DEPRESSION; META ANALYSIS; OUTCOMES RESEARCH; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PHOTOTHERAPY; PRACTICE GUIDELINE; PSYCHOTHERAPY; RATING SCALE; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYMPTOM; TECHNIQUE;

ACHIEVEMENT; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; EVIDENCE-BASED MEDICINE; EXERCISE; HUMANS; META-ANALYSIS; PHOTOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION;

EID: 1942473113     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. National Institute of Mental Health. Sequenced treatment alternatives to relieve depression. Bethesda (MD): National Institute of Mental Health; 2002. Available from http://www.edc.gsph.pitt.edu/stard/public/index.html-ssi.
2. Frank E, Prien R, Jarrett R, Keller M, Kupfer D, Lavori P, and others. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-5.
3. Paykel E. Achieving gains beyond response. Acta Psychiatr Scand Suppl 2002:12-7.
4. Parikh SV, Lam RW, and the CANMAT Depression Working Group. Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden. Can J Psychiatry 2001;46(Suppl 1):13S-20S.
5. Kennedy SH, Lam RW, Cohen NL, Ravindran AV, and the CANMAT Depression Working Group. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl 1):38S-58S.
6. Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002;27:269-80.
7. Cochrane AL. 1931-1971: a critical review, with particular reference to the medical profession. Medicines for the year 2000. London: Office of Health Economics; 1979. p 1-11.
8. The Cochrane Collaboration. Oxford (UK); Update Software Ltd; 2001.
9. Cochrane Collaboration Consumer Network. Research glossary. Available from http://www.cochraneconsumer.com/index.asp?SHOW=Understanding. Accessed March 30, 2003.
10. Anderson I. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161-78.
11. Cohen J. Statistical power analysis for the behavioural sciences. Orlando (FL): Academic Press; 1977.
12. Mallinckrodt C, Clark W, David S. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21.
13. Mallinckrodt C, Clark S, Carroll R, Molenbergh G. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat 2003;13:179-90.
14. Anderson I. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7(Suppl 1):11-7.
15. Anderson I. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36.
16. Barbui C, Hotopf M. Amitriptyline v the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001;178:129-44.
17. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404.
18. Thase M, Entsuah A, Rudolph R. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
19. Entsuah R, Huang M, Willard L. Venlafaxine and SSRIs: pooled remission analysis (mega-analysis of 31 studies of >7000 patients). Presented at the Meeting of the World Psychiatric Association; August 24-29, 2002: Yokohama (Japan).
20. Schatzberg A, Prather M, Keller M, Rush A, Laird L, Wright C. Clinical use of nefazodone in major depression: a 6-year perspective. J Clin Psychiatry 2002;63:18-31.
21. Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 2001;4:337-45.
22. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, and others. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002;22:379-87.
23. Licht R, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berlin) 2002;161:143-51.
24. Howland RH, Thase ME. What to do with SSRI nonresponders? J Psych Pract 1999;5:216-23.
25. Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, and others. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002;63:181-6.
26. Shelton R, Tollefson G, Tohen M, Stahl S, Gannon K, Jacobs T, and others. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4.
27. Rapaport M, Canuso C, Loescher A, Lasser R, Gharabawi G. Preliminary results from the ARISe-RD (Risperidone Augmentation in Resistant Depression) trial. Abstract number NR179. Presented at 156th American Psychiatric Association Annual Meeting; May 17-22, 2003; San Francisco (CA).
28. Westen D, Morrison K. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol 2001;69:875-99.
29. Casacalenda N, Perry J, Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry 2002;159:1354-60.
30. Burnand Y, Andreoli A, Kolatte E, Venturini A, Rosset N. Psychodynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr Serv 2002;53:585-90.
31. de Jonghe F, Kool S, van Aalst G, Dekker J, Peen J. Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord 2001;64:217-29.
32. Dunn R, Donoghue J, Ozminkowski R, Stephenson D, Hylan T. Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol 1999;13:136-43.
33. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, and others. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(Suppl 22):30-3.
34. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Patient adherence in the treatment of depression. Br J Psychiatry 2002;180:104-9.
35. Kutcher S, Leblanc J, Maclaren C, Hadrava V. A randomized trial of a specific adherence enhancement program in sertraline-treated adults with major depressive disorder in a primary care setting. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:591-6.
36. Simon G, Von KM, Ludman E, Katon W, Rutter C, Unutzer J, and others. Cost-effectiveness of a program to prevent depression relapse in primary care. Med Care 2002;40:941-50.
37. Mundt J, Clarke G, Burroughs D, Brenneman D, Griest J. Effectiveness of antidepressant pharmacotherapy: the impact of medication compliance and patient education. Depress Anxiety 2001;13:1-10.
38. Lawlor D, Hopker S. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ 2001;322:763-7.
39. Kritz-Silverstein D, Barrett-Connor E, Corbeau C. Cross-sectional and prospective study of exercise and depressed mood in the elderly: the Rancho Bernardo study. Am J Epidemiol 2001;153:596-603.
40. Mather A, Rodriguez C, Guthrie M, McHarg A, Reid I, McMurdo M. Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder: randomised controlled trial. Br J Psychiatry 2002;180:411-5.
41. Penninx B, Rejeski W, Pandya J, Miller M, Di Bari M, Applegate W, and others. Exercise and depressive symptoms: a comparison of aerobic and resistance exercise effects on emotional and physical function in older persons with high and low depressive symptomatology. J Gerontol B Psychol Sci Soc Sci 2002;57:P124-P132.
42. Singh N, Clements K, Singh M. The efficacy of exercise as a long-term antidepressant in elderly subjects: a randomized, controlled trial. J Gerontol A Biol Sci Med Sci 2001;56:M497-M504.
43. Jorm A, Christensen H, Griffiths K, Rodgers B. Effectiveness of complementary and self-help treatments for depression. Med J Aust 2002;176(Suppl):S84-S96.
44. Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001;16:239-52.
45. Shelton R, Keller M, Gelenberg A, Dunner D, Hirschfeld R, Thase M, and others. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001;285:1978-86.
46. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 2002;159:1361-6.
47. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:1807-14.
48. Nemets B, Stahl Z, Belmaker R. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-9.
49. Peet M, Horrobin D. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-9.
50. Terman M, Terman J, Quitkin F, McGrath P, Stewart J, Rafferty B. Light therapy for seasonal affective disorder. A review of efficacy. Neuropsychopharmacology 1989;2:1-22.
51. Lee T, Chan C. Dose-response relationship of phototherapy for seasonal affective disorder: a meta-analysis. Acta Psychiatr Scand 1999;99:315-23.
52. Thompson C. Light therapy in the treatment of seasonal and non-seasonal affective disorders: a meta-analysis of randomised controlled trials. Abstract number S4.4. J Affect Disord 2002;68:89.
53. Gaynes B, Ekstrom D, Hamer R, Jacobsen F, Nemeroff C, Suppes P, and others. Phototherapy: systematic review of the evidence. Abstract number 406. Presented at the 156th American Psychiatric Association Annual Meeting; May 17-22, 2003; San Francisco (CA).
54. Dwight-Johnson M, Sherbourne C, Liao D, Wells K. Treatment preferences among depressed primary care patients. J Gen Intern Med 2000;15:527-34.
55. Bedi N, Chilvers C, Churchill R, Dewey M, Duggan C, Fielding K, and others. Assessing effectiveness of treatment of depression in primary care. Partially randomised preference trial. Br J Psychiatry 2000;177:312-8.
56. Chilvers C, Dewey M, Fielding K, Gretton V, Miller P, Palmer B, and others. Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. BMJ 2001;322:772-5.
57. Ward E, King M, Lloyd M, Bower P, Sibbald B, Farrelly S, and others. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: clinical effectiveness. BMJ 2000;321:1383-8.
58. King M, Sibbald B, Ward E, Bower P, Lloyd M, Gabbay M, and others. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. Health Technol Assess 2000;4:1-83.
59. Judd L, Schettler P, Akiskal H. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am 2002;25:685-98.
60. Kunz N, Entsuah R, Lei D, Rudolph R, Hackett D. Venlafaxine extended release [XR] is superior to placebo in relapse prevention for patients with major depressive disorder Abstract. Meeting of the World Assembly for Mental Health; July 22-27, 2001; Vancouver (BC).
61. Kunz N, Entsuah R, Lei D, Rudolph R, Hackett D. Venlafaxine in the preventive treatment of recurrent major depressive disorder. Abstract. Meeting of the World Assembly for Mental Health; July 22-27, 2001; Vancouver (BC).
62. Thase M, Nierenberg A, Keller M, Panagides J. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001;62:782-8.
63. Koran L, Gelenberg A, Kornstein S, Howland R, Friedman R, De BC, and others. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001;65:27-36.
64. Perlis R, Nierenberg A, Alpert J, Pava J, Matthews J, Buchin J, and others. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol 2002;22:474-80.
65. Jarrett R, Kraft D, Doyle J, Foster B, Eaves G, Silver P. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 2001;58:381-8.
66. Weihs K, Houser T, Batey S, Ascher J, Bolden-Watson C, Donahue R, and others. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002;51:753-61.
67. Geddes J, Carney S, Davies C, Furukawa T, Kupfer D, Frank E, and others. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-61.
68. Keller M, Entsuah R, Kunz N. Remission after long-term treatment with venlafaxine. Abstract number P.1.166. J Eur Coll Neuropsychopharmacol 2002;12(Suppl 3):S237.
69. Nemeroff C, Entsuah R, Kunz N. Remission rates during long-term treatment of depression with venlafaxine. Presented at the American Psychiatric Association 155th Annual Meeting; May 18-23, 2002; Philadelphia (PA).